Story

FDA Plans to Appoint New Deputy Commissioners for Technology and Drugs, Report Says

ENTHMSVIIDZHZH-TWJAKOHI
Aug 25, 20262 min read
FDA Plans to Appoint New Deputy Commissioners for Technology and Drugs, Report Says
Text size
Background

The U.S. Department of Health and Human Services plans to appoint two new deputy commissioners at the Food and Drug Administration (FDA) to oversee technology and drugs, respectively, according to a CNBC report citing sources familiar with the plans.

Proposed Leadership Changes

The proposed restructuring would create two distinct senior roles. One deputy commissioner would focus on technology, including the rapidly evolving fields of artificial intelligence and digital healthcare. The other would have oversight of the agency's drug approval and regulation processes.

According to three people familiar with the matter cited in the report, Jared Seehafer is the leading candidate for the new technology-focused position. A candidate for the drug-focused role was not identified. The sources stressed that no final decisions have been made and the agency has not yet formally announced the appointments.

Context of Agency Transition

These potential changes come during a period of significant leadership transition at the FDA. Last week, President Donald Trump nominated White House policy aide Heidi Overton to lead the agency, an appointment that requires Senate confirmation. The previous FDA commissioner, Marty Makary, resigned in May after 13 months, reportedly following policy clashes with the White House.

Sample IUX Markets – In-articleAd

Since May, Kyle Diamantas has served as acting FDA chief. Under his temporary leadership, the agency has re-examined several regulatory decisions, including reopening consideration for therapies from companies like Regenxbio, uniQure, and Replimune.

What This Means for the Industry

The creation of a deputy commissioner for technology underscores the growing importance of AI and data science in pharmaceutical development and medical device innovation. For investors and companies in the biotech and health-tech sectors, this could signal the FDA's intent to develop clearer regulatory pathways for products utilizing these advanced technologies.

A dedicated deputy for drugs could also aim to bring more stability and focus to the pharmaceutical approval process, which has recently been the subject of public disagreements involving companies such as Sarepta and Moderna.

Read next

More on Stocks
Back to latest news

LATEST